Multivariate analysis for CIR, RFS, and OS
| Characteristic . | CIR . | RFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Platelets, × 109/L | — | — | — | — | 0.73 (0.62-0.87) | <.001 |
| No. of TP53 mutations >1 vs 1 | — | — | — | — | 1.98 (1.36-2.87) | <.001 |
| TP53mut VAF >40% vs ≤40% | 2.25 (1.32-3.86) | .003 | 2.21 (1.37-3.56) | .001 | 1.61 (1.17-2.21) | .003 |
| TP53 loss | — | — | — | — | 1.38 (1.01-1.89) | .04 |
| Transplantation (time dependent) | 0.18 (0.08-0.44) | <.001 | 0.30 (0.15-0.57) | <.001 | 0.27 (0.15-0.49) | <.001 |
| Characteristic . | CIR . | RFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Platelets, × 109/L | — | — | — | — | 0.73 (0.62-0.87) | <.001 |
| No. of TP53 mutations >1 vs 1 | — | — | — | — | 1.98 (1.36-2.87) | <.001 |
| TP53mut VAF >40% vs ≤40% | 2.25 (1.32-3.86) | .003 | 2.21 (1.37-3.56) | .001 | 1.61 (1.17-2.21) | .003 |
| TP53 loss | — | — | — | — | 1.38 (1.01-1.89) | .04 |
| Transplantation (time dependent) | 0.18 (0.08-0.44) | <.001 | 0.30 (0.15-0.57) | <.001 | 0.27 (0.15-0.49) | <.001 |
Dash (—) indicates lack of statistical significance in the multivariate model. Variables considered in the multivariate analysis included: age (years), white blood cells (× 109/L), platelets (× 109/L), bone marrow blast percentage, therapy-related AML vs non–therapy-related AML, secondary AML vs nonsecondary AML, cytogenetics (diploid vs nondiploid), n of TP53 mutations (>1 vs 1), TP53mut VAF, TP53 loss by cytogenetics, and transplantation (time dependent).